Turkovac

Turkovac
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Other names	ERUCOV-VAC
Routes of; administration	Intramuscular
Legal status
Legal status	Full list of Turkovac authorizations;

Turkovac[1] (pronunciation: ['tɜ:rkəvæk]) (temporarily named as ERUCOV-VAC[2]) is a COVID-19 vaccine developed by Health Institutes of Türkiye and Erciyes University.

Clinical trials

In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[3]

In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[4]

In June 2021, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[5]

Authorization

On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[6] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[7]

References

Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
"Domestic COVID-19 jab Turkovac begins Phase 3 trials in Turkey". Daily Sabah. 22 June 2021. Retrieved 23 June 2021.
Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov
Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov
"Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
"Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.
"Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Cakmak BN (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.

[2] "Domestic COVID-19 jab Turkovac begins Phase 3 trials in Turkey". Daily Sabah. 22 June 2021. Retrieved 23 June 2021.

[3] Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov

[4] Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov

[5] "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.

[6] "Turkey issues emergency-use authorization for its domestically produced vaccine". The New York Times. 22 December 2021. Retrieved 28 December 2021.

[7] "Turkey authorises use of own Turkovac Covid-19 vaccine". France 24. 23 December 2021. Retrieved 24 December 2021.

COVID-19 pandemic
Part of a series on the
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Investigations into origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Netherlands Ghana India New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Animals Black people Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBT community Long-term care Media coverage Mental health symptoms Migration Military Notable deaths Other health issues Politics diplomacy Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Society Ireland Malaysia New Zealand Russia UK US
COVID-19 portal